| 23rd week of 2013 patent applcation highlights part 36 |
| Patent application number | Title | Published |
|---|
| 20130142790 | Method of Treating Cancer Using a cMET and AXL Inhibitor and an ErbB Inhibitor - The present invention relates to a method of treating cancer in a patient comprising administering to the patient therapeutically effective amounts of:
| 2013-06-06 |
| 20130142791 | CYCLODEXTRIN NANOTECHNOLOGY FOR OPHTHALMIC DRUG DELIVERY - The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist. Further, the invention provides a method for treating a condition of the posterior segment and/or anterior segment of the eye comprising applying to the eye surface, in an amount which delivers to said segment or segments a therapeutically effective amount of a drug suitable for treating said condition, an ophthalmic composition which is as defined above. Nasal compositions and methods and ophthalmic and nasal compositions in powder form are also provided. | 2013-06-06 |
| 20130142792 | RAGE Fusion Protein Compositions And Methods Of Use - Disclosed are fusion proteins comprising a RAGE polypeptide, wherein the RAGE polypeptide comprises a fragment of a mammalian wild type RAGE peptide and at least one point mutation in the RAGE polypeptide portion of the fusion protein relative to the wild type RAGE peptide. The point mutation may remove and/or alter a glycosylation site or an enzyme cleavage site. Also disclosed are nucleic acids encoding such proteins as well as methods of using such proteins for treating RAGE-mediated pathologies. | 2013-06-06 |
| 20130142793 | BINDING DOMAIN-IMMUNOGLOBULIN FUSION PROTEINS - The invention relates to novel binding domain immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a hinge region polypeptide having either zero or one cysteine residue, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as monomeric polypeptides. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including immunotherapeutic applications. | 2013-06-06 |
| 20130142794 | Methods and Compositions for Increasing Arylsulfatase A Activity in the CNS - Provided herein are methods and compositions for treating a subject suffering from a deficiency in arylsulfatase A in the CNS. The methods include systemic administration of a bifunctional fusion antibody comprising an antibody to a human insulin receptor and an arylsulfatase A. | 2013-06-06 |
| 20130142795 | FUSION PROTEIN OF EXENDIN-4 AND ITS ANALOG, PREPARATION METHOD AND USE THEREOF - Provided are a fusion protein of Exendin-4 and its analog, the preparation method and use thereof. The fusion protein is obtained by fusing of Exendin-4 or its analog to Fc region of human IgG2 via a linking peptide, which has the better stability and prolonged serum half-life, and can be used for treating diabetes and obesity. | 2013-06-06 |
| 20130142796 | TREATMENT FOR ANGIOGENIC DISORDERS - Disclosed are pharmaceutical compositions comprising a therapeutically effective amount of a first compound, wherein the first compound binds the heparin-binding domain of the vascular endothelial growth factor (VEGF); and a therapeutically effective amount of a second compound, wherein the second compound binds to VEGF, thereby inhibiting the binding of VEGF to its cognate receptor. Also disclosed are methods of treating a VEGF-related disorder in a subject, the method comprising identifying a subject in need thereof, and administering to the subject a therapeutically effective amount of a first compound, wherein the first compound binds the heparin-binding domain of the vascular endothelial growth factor (VEGF); and a therapeutically effective amount of a second compound, wherein the second compound binds to VEGF, thereby inhibiting the binding of VEGF to its cognate receptor. | 2013-06-06 |
| 20130142797 | METHOD OF TREATING VIRUS-INDUCED CANCER - The present invention relates to methods of treating virus-induced cancer with the polypeptides that are capable of killing cells. The polypeptide comprises a targeting agent covalently attached to a channel-forming moiety. In a preferred embodiment, the channel-forming moiety comprises a colicin and the targeting agent is a reconstructed antibody mimetic derived from monoclonal antibody variants against Epstein-Barr virus gp350/220 | 2013-06-06 |
| 20130142798 | Methods for diagnosing cancer and decreasing metastasis by cancer cells - The invention provides a protein that is a tumor marker protein. This protein can be used to prepare antibodies that bind to the tumor marker protein. These antibodies can be used to reduce, or eliminate metastasis by cancer cells that produce the tumor marker protein. In addition, the invention provides methods that can be used to diagnose cancer, and metastasis by cancer cells. | 2013-06-06 |
| 20130142799 | Angiopoietin-2 Specific Binding Agents - Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies. | 2013-06-06 |
| 20130142800 | Mycobacterial Antigen Composition - There is provided an antigenic composition comprising (a) a first mycobacterial antigenic polypeptide or a first mycobacterial polynucleotide; and (b) a second mycobacterial antigenic polypeptide or a second mycobacterial polynucleotide; wherein: (i) said first mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 1 or 7, or a fragment thereof having at least 7 consecutive amino acids thereof; (ii) said first mycobacterial polynucleotide comprises a polynucleotide sequence encoding said first mycobacterial antigenic polypeptide; (iii) said second mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 5, or a fragment thereof having at least 7 consecutive amino acids thereof; and (iv) said second mycobacterial polynucleotide comprises a polynucleotide sequence encoding said second mycobacterial polypeptide. | 2013-06-06 |
| 20130142801 | ANTIBODY TO HUMAN ZCYTO-10 POLYPEPTIDE - Antibodies that which specifically bind to mammalian cytokine-like polypeptide, called Zcyto10, are described. The antibodies include monoclonal antibodies and those that where the antibody is an antigen-binding fragment. Zcyto10 is useful for promoting the healing of wounds and for stimulating the proliferation of platelets. | 2013-06-06 |
| 20130142802 | ANTIBODY MOLECULES TO ONCOGENIC ISOFORMS OF FIBROBLAST GROWTH FACTOR RECEPTOR-2 AND USES THEREOF - Antibody molecules that specifically bind to one or more isoforms expressed and/or associated with oncogenic phenotypes in a hyperproliferative cell (e.g., a cancerous or tumor cell) are disclosed. The isoform-binding antibody molecules can be used to treat, prevent and/or diagnose cancerous conditions and/or disorders. Methods of using the isoform-binding molecules to selectively detect oncogenic isoforms, to reduce the activity and/or induce the killing of a hyperproliferative cell expressing an oncogenic isoform in vitro, ex vivo or in vivo are also disclosed. Diagnostic and/or screening methods and kits for evaluating the function or expression of an oncogenic isoform are also disclosed. | 2013-06-06 |
| 20130142803 | Haemophilus Influenzae Type IV PILI - The invention described herein relates to a | 2013-06-06 |
| 20130142804 | Antibodies That Are Capable of Specifically Binding Tissue Factor Pathway Inhibitor - The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent. | 2013-06-06 |
| 20130142805 | COMBINATION OF ANTI-CTLA4 ANTIBODY WITH DIVERSE THERAPEUTIC REGIMENS FOR THE SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES - Compositions and methods are disclosed which are useful of the treatment and prevention of proliferative disorders. | 2013-06-06 |
| 20130142806 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF - The present invention provides anti-N3pGlu Aβ antibodies or antigen-binding fragment thereof. In addition, the present invention provides the use of the anti-N3pGlu Aβ antibodies or antigen-binding fragment thereof for the treatment of Alzheimers disease. | 2013-06-06 |
| 20130142807 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY - The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful. | 2013-06-06 |
| 20130142808 | ANTIBODY RECOGNIZING HUMAN LEUKEMIA INHIBITORY FACTOR (LIF) AND USE OF ANTI-LIF ANTIBODIES IN THE TREATMENT OF DISEASES ASSOCIATED WITH UNWANTED CELL PROLIFERATION - The invention relates to antibodies directed against human Leukemia Inhibitory Factor (LIF) and to a hybridoma cell line producing said antibodies. The invention also relates to a method for blocking/inhibiting the proliferation of stem cells, and to an in vitro method for the diagnosis of diseases associated with unwanted cell proliferation in a subject or for determining the predisposition of a subject to suffer from said disease associated with unwanted cell proliferation, or for prognosis of average life expectancy of a subject suffering from said disease. The therapeutic potential of said antibodies is based on observing that the inhibition of LIF can be used in therapeutic compositions for the treatment of diseases associated with unwanted proliferation. | 2013-06-06 |
| 20130142809 | METHODS OF TREATMENT USING AN IFN gamma INHIBITOR - The invention encompasses methods of treatment of interferon gamma (IFN-γ)-mediated diseases using IFN-γ inhibitors, such as anti-huIFN-γ antibodies, wherein levels of expression of one or more biomarkers are determined either before administration of the IFN-γ inhibitor and/or after administration. Also contemplated are methods of treatment using particular, pharmacodynamically effective doses of an anti-huIFN-γ antibody. | 2013-06-06 |
| 20130142810 | USE OF THE COMBINATION OF SEMAPHORIN-4D INHIBITORY MOLECULES AND VEGF INHIBITORY MOLECULES TO INHIBIT ANGIOGENESIS - Provided herein are methods for inhibiting tumor angiogenesis in a cancer patient, the method comprising administering to the subject an effective amount of a first isolated binding molecule which specifically binds to semaphorin-4D (SEMA4D) and an effective amount of a second isolated binding molecule which specifically binds to VEGF. | 2013-06-06 |
| 20130142811 | Antibody Modulating The Differentiation And Function Of Dendritic Cells Via Binding Intercellular Adhesion Molecule-1 And Use Thereof - The present invention relates to an antibody binding to human intercellular adhesion molecule-1 (ICAM-1) where the antibody is able to modulate the differentiation status of dendritic cells and prolong the graft survival. In addition, the present invention provides a pharmaceutical composition comprising the antibody, and method of using them for the treatment of disease. | 2013-06-06 |
| 20130142812 | ANTIBODY AND USE THEREOF - A cell growth inhibitor that includes, as an antibody component, an artificially produced anti-EGFR antibody having specific binding capacity to EGFR which is characterized in that an epitope therefor is in a cysteine-rich subdomain 2 (C2 domain) and/or in a ligand-binding domain 1 (L1 domain) among four subdomains contained in the extracellular domain of EGFR. | 2013-06-06 |
| 20130142813 | ANTIBODY BINDING TO LYSOPHOSPHATIDYLGLUCOSIDE, AND COMPOSITION COMPRISING THE SAME - In order to identify a factor demonstrating a repellent effect on axon extension of a neuron, lysophosphatidylglucoside (LPG) has been found to have an activity as a chemorepellent effect on axon guidance of a DRG sensory neuron specific to a neuron expressing TrkA, an NGF receptor. | 2013-06-06 |
| 20130142814 | IMMUNOSTIMULATORY SEQUENCE OLIGONUCLEOTIDES AND METHODS OF USING THE SAME - The invention provides immunomodulatory polynucleotides and methods for immunomodulation of individuals using the immunomodulatory polynucleotides. | 2013-06-06 |
| 20130142815 | ALPHA-METHYL-TRYPTOPHAN AS AN INHIBITOR OF INDOLEAMINE DIOXYGENASE - The present invention demonstrates for the first time that alpha-methyl-tryptophan is an inhibitor of the enzyme indoleamine diooxygenase (IDO). The present invention includes the use of alpha-methyl-tryptophan in methods of modulating immune responses and treating cancer and infections. | 2013-06-06 |
| 20130142816 | COMPOSITIONS AND METHODS FOR ENHANCING FERTILITY - Methods of promoting reproductive health in an animal, including humans, by administering an effective amount of a composition containing at least one transfer factor are provided. | 2013-06-06 |
| 20130142817 | MICROBIAL DELIVERY SYSTEM - The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity. | 2013-06-06 |
| 20130142818 | COMPLEXATION OF NUCLEIC ACIDS WITH DISULFIDE-CROSSLINKED CATIONIC COMPONENTS FOR TRANSFECTION AND IMMUNOSTIMULATION - The present invention is directed to a polymeric carrier cargo complex, comprising as a cargo at least one nucleic acid (molecule) and disulfide-crosslinked cationic components as a (preferably non-toxic and non-immunogenic) polymeric carrier. The inventive polymeric carrier cargo complex allows for both efficient transfection of nucleic acids into cells in vivo and in vitro and/or for induction of an (innate and/or adaptive) immune response, preferably dependent on the nucleic acid to be transported as a cargo. The present invention also provides, pharmaceutical compositions, particularly vaccines and adjuvants, comprising the inventive polymeric carrier cargo complex and optionally an antigen, as well as the use of such the inventive polymeric carrier cargo complex and optionally an antigen for transfecting a cell, a tissue or an organism, for (gene-)therapeutic purposes as disclosed herein, and/or as an immunostimulating agent or adjuvant, e.g. for eliciting an immune response for the treatment or prophylaxis of diseases as mentioned above. Finally, the invention relates to kits containing the inventive polymeric carrier cargo complex and/or the inventive pharmaceutical composition, adjuvant or vaccine in one or more parts of the kit. | 2013-06-06 |
| 20130142819 | LEISHMANICIDAL FORMULATION AND ITS USE - The present invention refers to pharmaceutical formulations obtained from the aqueous extract of the fungus | 2013-06-06 |
| 20130142820 | EXTRACTS OF CYATHUS STRIATUS MUSHROOMS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND A NEW CYATHUS STRIATUS STRAIN - A new and distinct variety of higher Basidiomycetes mushroom | 2013-06-06 |
| 20130142821 | Hapten-Carrier Conjugates and Uses Thereof - The present invention provides compositions comprising a conjugate of a hapten with a carrier in an ordered and repetitive array, and methods of making such compositions. The conjugates and compositions of the invention may comprise a variety of haptens, including hormones, toxins and drugs, especially drugs of addiction such as nicotine. Compositions and conjugates of the invention are useful for inducing immune responses against haptens, which can use useful in a variety of therapeutic, prophylactic and diagnostic regimens. In certain embodiments, immune responses generated using the conjugates, compositions and methods of the present invention are useful to prevent or treat addiction to drugs of abuse and the resultant diseases associated with drug addiction. | 2013-06-06 |
| 20130142822 | CONJUGATED VI SACCHARIDES - Two Vi conjugates have been prepared by carbodiimide-mediated synthesis, using adipic acid dihydrazide derivatized CRM | 2013-06-06 |
| 20130142823 | CMV GLYCOPROTEINS AND RECOMBINANT VECTORS - This invention also relates to recombinant vectors expressing one or more of the human CMV (HCMV) glycoproteins US2, US3, US6 and US11 or corresponding functional rhesus CMV (RhCMV) homologues Rh182, Rh184, Rh185 or Rh189, methods of making them, uses for them, expression products from them, and uses for the expression products. This invention also relates to recombinant cytomegalovirus vectors vectors lacking one or more of the glycoproteins, methods of making them, uses for them, expression products from them, and uses for the expression products. | 2013-06-06 |
| 20130142824 | NOVEL MODIFIED LIVE-ATTENUATED VACCINES (MLV) CREATED BY DNA SHUFFLING AGAINST PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS (PRRSV) - The present invention provides a novel infectious cDNA clone of porcine reproductive and respiratory syndrome virus (PRRSV), particularly for PRRSV strain VR2385; an improved DNA-launched reverse genetics system for PRRSV; infectious chimeric PRRSV viruses generated through DNA shuffling; modified live- attenuated virus vaccines (MLV) using DNA shuffled chimeric viruses; chimeric viral proteins produced through shuffled chimeric viruses; PRRSV antigens and subunit vaccines based on shuffled chimeric viral proteins; and method of producing broadly protective PRRSV vaccines using DNA shuffling techniques. Particularly, the present invention provides infectious chimeric viruses generated by DNA shuffling of the GP5 genes of genetically distinct strains of PRRSV; modified live-attenuated vaccines comprise infectious chimeric viruses containing the shuffled GP5 genes and/or other shuffled PRRSV proteins (such as GP2, GP3, GP4, M, and non-structural proteins); broadly -protective subunit vaccines comprising PRRSV chimeric shuffled GP5 protein and/or other shuffled PRRSV proteins (such as GP2, GP3, GP4, M, and non-structural proteins). | 2013-06-06 |
| 20130142825 | METHOD OF PREVENTING AND TREATING INFLAMMATORY DISEASES AND DISORDERS WITH ABSCISIC ACID - The present invention relates to the use of a therapeutically effective amount of abscisic acid (ABA) or its analogs to treat or prevent inflammation induced by exposure to lipopolysaccharide (LPS) or respiratory inflammation. The invention also relates to methods and composition for enhancing vaccine efficacy using ABA. | 2013-06-06 |
| 20130142826 | RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS) PRODUCED IN TRANSGENIC PLANTS EXPRESSING HEMAGGLUTININ - A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plant lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines. | 2013-06-06 |
| 20130142827 | INDUCTION OF IMMUNE RESPONSE - Provided are methods and compositions that can be used to treat subjects having a viral infection by provoking an immune response using newly discovered antigens that are non-naturally occurring variations on viral glycoproteins. For example, provided are viral glycoproteins or a fragments thereof, or, DNA constructs encoding for such viral glycoproteins or fragments thereof, wherein the glycoprotein or fragment comprises a glycosylation sequon that includes a non-templated aspartic acid residue. | 2013-06-06 |
| 20130142828 | BACTERIAL RIBONUCLEIC ACID CELL WALL COMPOSITIONS AND METHODS OF MAKING AND USING THEM - The present invention relates to novel mycobacterial compositions containing RNA and cell walls, and methods for making and using these compositions. These compositions have immune stimulating and anti-cancer activity. The present invention also relates to a synthetic medium for the cultivation of mycobacteria. | 2013-06-06 |
| 20130142829 | Mutant Parasites for Use as Vaccines and Platforms for Screening for Compounds - Cloning and characterization of a TgIF2α kinase from | 2013-06-06 |
| 20130142830 | Tolerogenic Plasmacytoid Dendritic Cells Co-Expressing Cd8-Alpha And Cd8-Beta And Methods Of Inducing The Differentiation Of Regulatory T Cells Using Same - This invention discloses an unexpected discovery that plasmacytoid dendritic cells (pDCs) may be segregated into immunogenic or tolerogenic species based on novel biomarkers discovered herein. Exemplary biomarkers include CD8α | 2013-06-06 |
| 20130142831 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to compounds of formula (I): | 2013-06-06 |
| 20130142832 | NUCLEIC ACID/ POLYSACCHARIDE COMPLEX - An object of the present invention is to provide a highly stable nucleic acid-polysaccharide complex of an siRNA and schizophyllan. A nucleic acid-polysaccharide complex is formed by adding polydeoxyadenine in which at least part of the phosphodiester link portion is phosphorothioated to an siRNA and allowing the siRNA and schizophyllan to form a complex. | 2013-06-06 |
| 20130142833 | CIRCULATION OF COMPONENTS DURING HOMOGENIZATION OF EMULSIONS - An improved method for the manufacture of an oil-in-water emulsion involves circulation of emulsion components between a first container and a second container via a homogenizer and/or via a microfluidization device. Usefully, all of the emulsion components from the first container are emptied before being returned. | 2013-06-06 |
| 20130142834 | LOCAL DELIVERY OF DRUGS FROM SELF ASSEMBLED COATINGS - The invention relates to oligofluorinated coatings and their use in drag delivery The oligofluorinated coatings are compositions comprising formula (XVII). These coatings are used in a method of delivering a biologically active agent to a tissue surface in a mammalian tissue This method occurs by contacting the surface with the coating including an oligofluorinated oligomer and a biologically active agent wherein the coating resides on the tissue surface and release the biologically active agent to the tissue surface. | 2013-06-06 |
| 20130142835 | SYNTHETIC SCAFFOLDS AND ORGAN AND TISSUE TRANSPLANTATION - Articles, compositions, and methods for growing tissues and organs using bioreactors, including rotating bioreactors, are provided. Synthetic scaffolds for growing artificial tissue and organ transplants are also provided. | 2013-06-06 |
| 20130142836 | COMPOSITION AND METHOD FOR INHIBITING, PREVENTING, OR AMELIORATING COMPLICATIONS ASSOCIATED WITH INGESTION OF A MEDICINAL, CHEMICAL, OR BIOLOGICAL SUBSTANCE OR AGENT - The application relates, in part, to a therapeutic composition comprising a pharmaceutically active agent and a diarrheagenic agent. | 2013-06-06 |
| 20130142837 | CELLULOSIC GEL COMPOSITION WITH IMPROVED VISCOSITY STABILITY - The present invention is directed to cellulosic gel compositions having improved viscosity stability through the exclusion of particular antioxidants and/or the exclusion of chemical entities that tend to produce free radicals. Preferably, the composition is an ophthalmic cellulosic gel composition that is suitable as a multi-dose composition. | 2013-06-06 |
| 20130142838 | COMPOSITIONS CONTAINING MICRONIZED TANAPROGET PREPARED BY WET GRANULATION - Compositions, preferably pharmaceutical compositions, containing micronized tanaproget, or pharmaceutically acceptable salt thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, butylated hydroxyanisole, povidone, and magnesium stearate, are provided. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic to disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake. | 2013-06-06 |
| 20130142839 | METHOD AND SYSTEM FOR ADDING SENSORY CONDITIONING CUES IN A PHARMACOTHERAPEUTIC REGIMEN - A method and system for administering pharmaceutical agents to a subject is provided. The system includes a course of treatment regimen, which includes a prescribed order of medicine amounts for periodic administration to the subject in the prescribed order. The amount of medicine includes a dose of at least one active pharmacological agent (APA) and an amount of at least one non-active pharmacological agent (NPA). The NPA provides at least one non-visual sensory cue. The dosage amounts of the APA contained within the amounts of medicine periodically administered in the prescribed order are varied within the course of treatment regimen, and the amount of the NPA contained within the amounts of medicine periodically administered in the prescribed order are held constant within the course of treatment regimen. | 2013-06-06 |
| 20130142840 | DENSE FIBRILLAR COLLAGEN MATRICES FOR TISSUE REPAIR AND THE PREPARATION METHOD THEREOF - Method for preparing a homogeneous collagen-based material by concentration of a collagen solution, includes bringing a collagen solution into contact by way of continuous injection and use of the material for tissue repair. | 2013-06-06 |
| 20130142841 | Calcium Carbonate Granulation - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available. | 2013-06-06 |
| 20130142842 | Calcium Carbonate Granulation - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available. | 2013-06-06 |
| 20130142843 | Calcium Carbonate Granulation - Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available. | 2013-06-06 |
| 20130142844 | TISSUE IMPLANTS FOR IMPLANTATION AND METHODS OF PREPARING THE SAME - A method is provided for preparing a tissue implant for implantation. The method includes harvesting a tissue material from a human or an animal donor, treating the tissue material in a nuclease-containing solution, and thereafter treating the tissue material with an alkaline alcohol solution. The nuclease-containing solution includes an antimicrobial. The alkaline alcohol solution comprises sodium hydroxide and ethanol. | 2013-06-06 |
| 20130142846 | Modified Release Analgesic Suspensions - A pharmaceutical dosage form comprising non-steroidal-anti-inflammatory drugs, in particular propionic acid derivatives such as ibuprofen, along with a second active ingredient having a shorter therapeutically effective plasma concentration duration, such as phenylephrine, and methods of administering the same are provided. This method provides improved therapeutic effect, in particular pain relief along with decongestant relief, over extended time periods. | 2013-06-06 |
| 20130142847 | S-ADENOSYLMETHIONINE FORMULATIONS WITH ENHANCED BIOAVAILABILITY - Provided herein are compositions and methods to enhance the absorption of S-adenosylmethionine (SAMe) and methods of treating various disorders or diseases using non-parenteral SAMe formulations with enhanced-absorption and improved bioavailability. In certain embodiments, the enhanced bioavailability formulations provided herein may be used to treat a variety of diseases or disorders, such as for example, psychiatric disorders including, generalized anxiety disorder, obsessive compulsive disorder, post traumatic stress disorder, panic disorder, depressive disorders (e.g. major clinical depression) and dysthymia; as well as treating liver disorders, cancer, autoimmune disorders, inflammatory disorders, joint disorders, gastrointestinal disorders and cardiovascular disease. | 2013-06-06 |
| 20130142848 | PREPARATION FOR TREATMENT OF SPINAL CORD INJURY - The present invention is a solid sustained-release formulation comprising an agent for inhibiting semaphorin 3A as an active ingredient, which comprises an agent for inhibiting semaphorin 3A and pharmaceutically acceptable hardly water-soluble solid substance, in which the carrier is silicone. | 2013-06-06 |
| 20130142849 | CONTROLLED RELEASE FORMULATIONS OF DRONEDARONE - The present invention relates to controlled release formulation of dronedarone or pharmaceutically acceptable salts, esters, metabolites, prodrugs or enantiomers thereof and controlled release polymers. The use of controlled release formulations of Dronedarone would improve the bioavailability and the patient compliance with reduction in number of dosages to be taken per day. | 2013-06-06 |
| 20130142850 | ALLOPLASTIC INJECTABLE DERMAL FILLER AND METHODS OF USE THEREOF - A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent, said method comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent, is also provided. A method of augmenting soft tissue to provide long-term reduction of a skin defect, said method comprising stimulating collagen beneath the skin defect is further provided. In an embodiment of the method of augmenting soft tissue, the stimulation of collagen production is effected by injecting into the deep reticular dermis an a dermal filler, said dermal filler being an alloplastic injectable suspension and comprising a biocompatible and pliable material and a physiologically acceptable suspending agent. | 2013-06-06 |
| 20130142851 | Compositions Comprising Components Coated With a Liquid Impermeable but Gas Permeable Layer, Use Thereof for Treating Cutaneous and Other Exocrine Gland Diseases - The present invention relates to medically efficacious agents coated with substance that forms a liquid impermeable but gas permeable layer, the treatment of medical conditions therewith, and particularly medical conditions at least partially characterised by blockage or other malfunction of ducts of exocrine glands and especially ducts of sweat glands. | 2013-06-06 |
| 20130142852 | NANOFIBER LAMINATE SHEET - A nanofiber laminate sheet including a layer of a nanofiber of a water insoluble polymer and a layer of a water soluble polymer containing a cosmetic component or a medicinal component. The nanofiber is preferably colored. The layer of a water soluble polymer is preferably a layer of a nanofiber of the water soluble polymer containing the cosmetic component or the medicinal component. The nanofiber laminate sheet is suited for use as a cosmetic sheet for makeup. | 2013-06-06 |
| 20130142853 | Skin Cosmetic - The present invention is a skin cosmetic comprising agar hydrogel particles having an average particle size of 0.2-5 mm obtained by stirring and cooling, in an oil based solvent, an agar aqueous solution prepared such that the breaking stress after the cooling/solidification is 0.005-0.1 MPa and an oil based gel prepared by mixing fine particles of silicone that are three-dimensionally cross-linked chemically and silicone oil and/or hydrocarbon oil. | 2013-06-06 |
| 20130142854 | MANICURE COMPOSITION - Provided is a manicure composition of a French nail type which has less disturbance of the lines brought about by a base color and a topcoat and is quickly dried, which does not cause dew condensation on the coating film under a moist environment for coating and has less leveling and less irregular color and which is excellent in a drying property, an adhesive property, flexibility, a masking property, a finished property, a discharge performance and a restirring property. The above manicure composition comprises at least ethanol and propylene glycol monomethyl ether as a solvent, titanium oxide A having an average primary particle diameter of 200 to 400 nm, titanium oxide B having an average primary particle diameter of 10 to 80 nm, an acrylic resin, polyether-modified polydimethylsiloxane and a plasticizer. | 2013-06-06 |
| 20130142855 | MODIFIED SOPHOROLIPIDS COMBINATIONS AS ANTIMICROBIAL AGENTS - A method to control, inhibit, and kill pathogens and normal microbial strains that includes, but not limited to plant, animal and human pathogens, biofilm forming microbes, biofouling microbes, algae, fungi, bacteria, virus and protozoa using natural SL, MSL derivative and combinations thereof encompassed by the combination invention. | 2013-06-06 |
| 20130142856 | COMPOSITIONS COMPRISING A GERMINANT AND AN ANTIMICROBIAL AGENT - The present invention provides an antiseptic composition comprising a germinant and an antimicrobial agent, wherein the germinant increases a pathogen's susceptibility to attack from the antimicrobial agent and wherein the antimicrobial agent does not inhibit the germinant. The present invention also provides an antiseptic wipe, handwash or paint comprising such antiseptic composition and a method of sterilizing a surface using such a composition. | 2013-06-06 |
| 20130142857 | TOILET PAPER - The invention relates to toilet paper which can be used to satisfy human sanitary and hygiene requirements and makes it possible to reduce toilet paper consumption because the central sector of a sheet of the toilet paper has a higher average density and/or a higher average elasticity than the outer sector of said sheet of toilet paper, wherein the outer sector of the sheet of toilet paper completely or partially surrounds the central sector. | 2013-06-06 |
| 20130142858 | DRUG DELIVERY DEVICES FOR DELIVERY OF OCULAR THERAPEUTIC AGENTS - Drug delivery devices comprising a non-bioabsorbable polymer structure configured to support a composition comprising an active agent. The devices include a plurality of portions fused together and a recess configured to support the composition. At least one of the portions includes an impermeable polymer and at least one other portion includes a rate-limiting water-permeable polymer. The rate-limiting water-permeable polymer allows for transportation of the active agent to an exterior of the device. | 2013-06-06 |
| 20130142859 | COMPOSITIONS AND METHODS FOR THE SUSTAINED RELEASE OF BETA-ALANINE - Methods and compositions are provided for increasing the anaerobic working capacity of muscle and other tissues. Also provided are compositions formulated for the sustained release of free beta-alanine. Also provided is a dietary supplement formulated, for example, as a solid food product, an edible suspension, liquid or semi-liquid as described herein. | 2013-06-06 |
| 20130142860 | MATERIAL COMPOSITIONS WHICH COMPRISE ADULT STEM CELLS OBTAINED FROM EXOCRINE GLANDULAR TISSUE, IN PARTICULAR FOR USE IN REGENERATIVE MEDICINE - The invention relates to material compositions comprising adult stem cells obtained from exocrine gland tissue and a supporting matrix having the shape of a thread structure and/or of a net. The supporting matrix preferably consists of a plastic material which is physiologically acceptable and degradable in the body. The material compositions of the invention are in particular suited for use in regenerative medicine, e.g. for regeneration of injured or damaged myocard tissue. | 2013-06-06 |
| 20130142861 | Compositions And Method For Detecting And Treating Abnormal Liver Homeostasis And Hepatocarcinogenesis - Novel compositions and methods for detecting and preventing and/or treating abnormal liver homeostasis and hepatocarcinoma as well as conditions that may be regulated by microRNA-122 are provided. A transgenic knockout non-human animal comprising a disruption in the endogenous mir-122 gene is also provided. | 2013-06-06 |
| 20130142862 | Tumor-Specific Delivery of Therapeutic Agents Via Liposomase - is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with | 2013-06-06 |
| 20130142863 | PHOSPHATIDYLCHOLINE LIPID LIPOSOMES AS BOUNDRY LUBRICANTS IN AQUEOUS MEDIA - The invention provides a method for lubricating one or more surfaces, comprising applying gel-phase liposomes onto said one or more surfaces, wherein the temperature of said surface(s) at the time of lubrication is below the phase transition temperature Tm of said liposomes. The method can be used for lubricating non-biological surfaces, and also for lubricating the surfaces of a biological tissue in a mammalian subject, e.g., for treating joint dysfunction. | 2013-06-06 |
| 20130142864 | IN VIVO TARGETING OF DENDRITIC CELLS - The invention provides a composition for modulating immunity by the in vivo targeting of an antigen to dendritic cells. The composition comprises: a preparation of antigen-containing membrane vesicles or antigen-containing liposomes which have on their surfaces a plurality of metal chelating groups; and, a ligand for a receptor on the dendritic cells, the ligand being linked to a metal chelating group via a metal affinity tag on the ligand. The composition further includes an immunomodulatory factor. A process for preparing the composition is also provided. The invention further provides a method of modulating an immune disorder, and methods of treating tumours and infections. | 2013-06-06 |
| 20130142865 | FIXED DOSING OF HER ANTIBODIES - The present invention concerns fixed dosing of HER antibodies, such as Pertuzumab. | 2013-06-06 |
| 20130142866 | COMPOSITIONS AND METHODS FOR IMPROVED ORGAN TRANSPLANT PRESERVATION AND ACCEPTANCE - The invention provides a novel aqueous composition for the storage and preservation of transplants, such as organ or tissue allografts. The composition comprises the compound N-octanoyl dopamine in solubilised form. The composition may also be administered as a pre-treatment of transplant donors. Moreover, it may be used in transplant recipients, optionally in combination with immunosuppressants. | 2013-06-06 |
| 20130142867 | CANCER-TARGETING PEPTIDES AND USES THEREOF IN CANCER TREATMENT AND DIAGNOSIS - Cancer-targeting peptides having a PX | 2013-06-06 |
| 20130142868 | Circumferential Aerosol Device for Delivering Drugs to Olfactory Epithelium and Brain - Methods of delivering a pharmaceutical compounds directly to the olfactory epithelium of a mammal by providing a pharmaceutical aerosol suspension comprising an aerosol and the pharmaceutical compound; aerosolizing the suspension to generate a stream of droplets, the stream having a rotational component, and, delivering the droplets directly to the olfactory epithelium, wherein at least 15% of the droplets are delivered directly to the olfactory deposition. The pharmaceutical compound may be encapsulated within a liposome nanoparticle. | 2013-06-06 |
| 20130142869 | Compositions Comprising Non Steroidal Anti-inflammatory Drugs and Methods for Use Thereof - The invention provides analgesic, antipyretic and anti-inflammatory compositions containing epilactose in combination with non-steroidal anti-inflammatory drugs and pharmaceutically acceptable zinc compounds. This invention relates to the use of these novel compositions for significantly improved and synergistic safety and therapeutic profiles. | 2013-06-06 |
| 20130142870 | NERAMEXANE MULTIPLE UNIT DOSAGE FORM - Unit comprising neramexane, a pharmaceutically acceptable salt, solvate, conjugate, prodrug, polymorphic form, isomer, or derivative thereof; and a release-controlling excipient; wherein said unit has a diameter of from 0.1 to less than 6 mm. | 2013-06-06 |
| 20130142871 | ORAL DOSAGE FORM OF DEFERASIROX - The invention relates to an oral dosage form containing deferasirox, binder, disintegrant and optionally wicking agent, wherein the introduction of the dosage form into water leads to a suspension wherein the suspended particles have an average particle size (D50) of 20 μm to 120 μm, and also to a method of producing it. | 2013-06-06 |
| 20130142872 | EMP2: Ethyl-Methyl, di Methyl, tri Methyl Pyruvate Acid Esters: A Tool for Regulating HbA1c and a Riboswitch Activator - The invention is a novel series of compounds represented by general formula, its analogs, tautomeric forms, stereoisomers, pharmaceutically acceptable salts and polymorphs wherein said compound described is a group of antisense molecules possessing immediate global cellular penetration due to their molecular structure and lipophilicity. The molecules are combinations of ethyl and methyl pyruvates. They induce riboswitch activity and reduce target RNA and nucleic acids such as HbA1c. They reduce inflammation and enhance energy production. These features improve therapeutic outcomes of diabetes, neuropathy and cellular aging. | 2013-06-06 |
| 20130142873 | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-- 3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE - Provided herein are compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, solid forms, isotopologues and metabolites thereof, and methods of their use for the treatment of a disease, disorder, or condition. | 2013-06-06 |
| 20130142874 | PHARMACEUTICAL COMPOSITIONS BASED ON DICLOFENAC - New pharmaceutical compositions for oral use containing Diclofenac together with alkali metal bicarbonates in amounts of from 20 to 80 by weight with respect to Diclofenac are described. These compositions are entirely palatable and free from any unpleasant taste or other side effects; in particular, these formulations permit to obtain in human patients higher C | 2013-06-06 |
| 20130142875 | METHODS AND COMPOSITIONS FOR TREATING PROSTATE CANCER - Treatment of prostate cancer by regional and prolonged release of one or more nucleotide-based RNAi agents is provided. | 2013-06-06 |
| 20130142876 | AMPHIPATHIC LIPID-BASED SUSTAINED RELEASE COMPOSITIONS - Chewable sustained release compositions and their methods of production are provided. The sustained release compositions contain amphipathic lipids, which are used to encapsulate various drugs and active ingredients. | 2013-06-06 |
| 20130142877 | PHARMACEUTICAL DOSAGE FORM COMPRISING ONE OR MORE ANTIRETROVIRAL ACTIVE INGREDIENTS - The invention relates to a pharmaceutical dosage form comprising one or more antiretroviral active ingredients in the form of a solid dispersion or solid solution in a matrix, wherein said matrix comprises an amino(meth)acrylate copolymer, characterized in that the matrix does not contain any essential amounts of pharmaceutically acceptable surfactants with an HLB value from 12 to 18 and in that the matrix comprises a mono carboxylic acid or an alcohol with 12 to 22 carbon atoms or both. | 2013-06-06 |
| 20130142878 | PEPTIDE PARTICLE FORMULATION - A composition as disclosed is comprised of a plurality of groups of particles. The particles are comprised of a biocompatible polymer which may be a co-polymer such as PLGA combined with a peptide of a sequence of interest, e.g. a sequence which corresponds to a sequence presented on a surface of a cell infected with a virus. A plurality of different groups of particles are provided in the formulation wherein the particles within any single group include peptides of identical amino acid sequence. The particles are sized such that they are sufficiently large so as to prevent more than the contents of a single particle from being presented to a single immune system cell. | 2013-06-06 |
| 20130142879 | SUSPENSION FORMULATIONS - The present invention relates to suspension formulations, especially those for delivering a pharmaceutically active agent in aerosol form using a spray or aerosol device, such as a pressurised metered dose inhaler (pMDI). The formulations may be for pulmonary, nasal, buccal or topical administration, but are preferably for pulmonary inhalation. | 2013-06-06 |
| 20130142880 | BECLOMETHASONE DIPROPIONATE COMPOSITIONS IN MODIFIED-RELEASE GASTRO-RESISTANT MICROSPHERES AND PROCESS FOR OBTAINING THEM - The present invention refers to pharmaceutical beclomethasone dipropionate compositions in modified-release gastro-resistant microspheres and to their oral use in the treatment of inflammatory pathologies of the intestinal tract. Said compositions in microspheres comprise: a) a core consisting of a microsphere of inert material; b) a first intermediate coating comprising beclomethasone dipropionate and at least one physiologically acceptable excipient; c) a second modified-release gastro-resistant coating. The present invention also refers to a process for obtaining said compositions. | 2013-06-06 |
| 20130142881 | Lip Balm Composition - A lip balm composition of natural ingredients, comprising : 54-70 wt. % of one or more oils, 22-28 wt. % beeswax, 3-4 wt. % propolis, 3-5 wt. % pomace, 0.02-3.2 wt. % antioxidant, and optional ingredients, whereby all components add to 100 wt. %. | 2013-06-06 |
| 20130142882 | METHODS AND COMPOSITIONS FOR TREATMENT, MODIFICATION AND MANAGEMENT OF BONE CANCER PAIN - The present invention provides methods and compositions for treating, preventing, modifying (reducing), or managing bone cancer pain by cyclohexenone compounds. | 2013-06-06 |
| 20130142883 | MEDICAL FOOD FOR THE DIETARY MANAGEMENT OF DEPRESSION AND ANXIETY AND METHODS THEREOF - A medical food for the dietary management of depression and/or anxiety includes water containing from 0.0002 to 0.0278 mol. % of isotopologue HOD, preferably, from 0.0178 to 0.0278 mol. % of isotopologue HOD. Further, a method for the dietary management of depression and/or anxiety uses the step of administering to a subject in need thereof the medical food. Further, a method of the treatment of depression includes the steps of administering to a subject an antidepressant drug and administering to the subject the medical food. Further, a method of the treatment of anxiety includes the steps of administering to a subject an antianxiety drug and administering to the subject the medical food. | 2013-06-06 |
| 20130142884 | Cream for Applying on a Body - A cream has at least two components, one of the components includes stable water clusters, and the cream is applied on a body to produce local surface effects, local deep effects, and non-local effects in the body. | 2013-06-06 |
| 20130142885 | IMMOBILIZED METALLIC NANOPARTICLES AS UNIQUE MATERIALS FOR THERAPEUTIC AND BIOSENSOR APPLICATIONS - The present invention relates to compositions and methods by which surface modification techniques can be used to modify wide range polymeric or metal substrates using metal nanoparticles. | 2013-06-06 |
| 20130142886 | COMPOSITIONS OF DIBROMOMALANOMIDE AND THEIR USE AS BIOCIDES - A biocidal composition comprising 2,2-dibromomalonamide and a metal selected from silver, copper, and mixtures thereof, and its use for the control of microorganisms in aqueous and water-containing systems. | 2013-06-06 |
| 20130142887 | USE OF HISTONE ACETYLTRANSFERASE INHIBITORS AS NOVEL ANTI-CANCER THERAPIES - The present invention provides methods for treating cancer comprising inhibiting the activity of p300/CBP histone acetyltransferase (HAT). Also provided are p300/CBP HAT inhibitors for treating a subject having cancer. In addition, the present invention includes biomarkers for p300/CBP HAT inhibition, which are used to i) monitor the effectiveness of cancer therapy, and ii) identify anti-cancer agents for use in combination therapy. | 2013-06-06 |
| 20130142888 | N-ACETYL-DL-LEUCINE, NEUROPROTECTIVE AND RETINOPROTECTIVE MEDICAMENT - The invention relates to a medicament, the active principle of which is a leucine and, for example, a N-ACETYL-DL-LEUCINE. It can be applied to the prevention and/or treatment of eye diseases or disorders and especially of hereditary dystrophies of the retina, glaucomatous neuropathy, glaucoma, macular degeneration, myopia, presbyopia, hypermetropia, astigmatism, all the ophtalmologic diseases or disorders inducing a decrease of visual function and/or age-related physiological vision decline. | 2013-06-06 |
| 20130142889 | COMPOSITION COMPRISING THE EXTRACT OF PHYSALIS ALKEKENGI VAR. FRANCHETI HORT AS AN ACTIVE INGREDIENT FOR PREVENTING AND TREATING INFLAMMATORY DISEASES - The present invention is related to the inventive compositions comprising the extract of Physalis alkekengi var francheti Hort showing potent anti-inflammatory effect through various experiments, therefore, it can be used as the effective and safe therapeutics or health food for treating and preventing inflammatory diseases | 2013-06-06 |
| 20130142890 | COMPOSITION AND USES FOR INFLUENCING HAIR GROWTH - The invention describes a combination of at least one aromatase inhibitor selected from the group of chemical-synthetic aromatase inhibitors and aromatase inhibition exhibiting extracts of soya beans and rapeseed, respectively, and at least one plant extract that contains one or more active ingredient substance(s) extracted from the plant, which is(are) selected from the group of 5α reductase type I and/or type II inhibitors and androgen receptor blockers, said combination being contained for example in a composition and having special properties for influencing hair growth. Uses of this combination are also described. | 2013-06-06 |
